Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tonix Pharm Holdings (TNXP)

Tonix Pharm Holdings (TNXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 171,999
  • Shares Outstanding, K 12,788
  • Annual Sales, $ 10,090 K
  • Annual Income, $ -130,040 K
  • EBIT $ -100 M
  • EBITDA $ -96 M
  • 60-Month Beta 1.88
  • Price/Sales 7.99
  • Price/Cash Flow N/A
  • Price/Book 0.60

Options Overview Details

View History
  • Implied Volatility 153.51% (-33.73%)
  • Historical Volatility 52.79%
  • IV Percentile 88%
  • IV Rank 62.70%
  • IV High 187.25% on 03/05/26
  • IV Low 96.80% on 01/21/26
  • Expected Move (DTE 11) 2.81 (20.86%)
  • Put/Call Vol Ratio 0.07
  • Today's Volume 91
  • Volume Avg (30-Day) 185
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 3,678
  • Open Int (30-Day) 3,594
  • Expected Range 10.65 to 16.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.16
  • Number of Estimates 3
  • High Estimate -2.85
  • Low Estimate -3.65
  • Prior Year -9.77
  • Growth Rate Est. (year over year) +67.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.07 +2.45%
on 03/06/26
16.69 -19.77%
on 02/10/26
-2.86 (-17.60%)
since 02/09/26
3-Month
13.07 +2.45%
on 03/06/26
20.56 -34.87%
on 12/12/25
-6.21 (-31.68%)
since 12/09/25
52-Week
12.35 +8.42%
on 03/11/25
69.97 -80.86%
on 08/14/25
+0.37 (+2.84%)
since 03/07/25

Most Recent Stories

More News
Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Commercially launched in the U.S. in November 2025, TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime is the first new FDA-approved treatment for fibromyalgia in adults...

TNXP : 13.39 (-0.45%)
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced...

TNXP : 13.39 (-0.45%)
Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced...

TNXP : 13.39 (-0.45%)
Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced...

TNXP : 13.39 (-0.45%)
Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism,...

TNXP : 13.39 (-0.45%)
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today...

TNXP : 13.39 (-0.45%)
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today...

TNXP : 13.39 (-0.45%)
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study Expect to have investigational product  of TNX-4800 (anti-Borrelia...

TNXP : 13.39 (-0.45%)
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain Compelling safety and pharmacokinetic profiles in animals support IND-enabling...

TNXP : 13.39 (-0.45%)
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

CHATHAM, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated commercial-stage biotechnology company today...

TNXP : 13.39 (-0.45%)

Business Summary

Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102,...

See More

Key Turning Points

3rd Resistance Point 14.40
2nd Resistance Point 14.06
1st Resistance Point 13.75
Last Price 13.39
1st Support Level 13.11
2nd Support Level 12.77
3rd Support Level 12.46

See More

52-Week High 69.97
Fibonacci 61.8% 47.96
Fibonacci 50% 41.16
Fibonacci 38.2% 34.36
Last Price 13.39
52-Week Low 12.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar